Published in final edited form as:

Org Lett. 2019 April 05; 21(7): 2200–2203. doi:10.1021/acs.orglett.9b00125.

Scalable Synthesis of Orthogonally Protected β -Methyllanthionines by Indium(III)-Mediated Ring Opening of Aziridines

Ziran Li, Zachary Gentry, Brennan Murphy, and Michael S. VanNieuwenhze*

Department of Chemistry, Indiana University, 800 East Kirkwood Avenue, Bloomington, Indiana 47405-7102, United States

Abstract

Lantibiotics are a class of peptide antibiotics with activity against most Gram-positive bacteria. Lanthionine (Lan) and β -MeLan are unusual thioether-bridged, non-proteinogenic amino acids, which are characteristic features of lantibiotics. In this paper, we report the facile stereoselective synthesis of β -methyllanthionines with orthogonal protection by nucleophilic ring opening of aziridines. This method leads to an expedient access to β -methyllanthionines and allows production of over 30 g of β -methyllanthionine in a single batch.

Graphical Abstract

Rapid outgrowth of multidrug-resistant bacteria poses a very serious threat to human health. Unfortunately, the weapons in our current antibiotic arsenal have become less and less effective in treating bacterial infections.¹ Discovering novel antibacterial agents, which are active against multiresistant bacteria, is a significant global health concern. In view of their unique modes of action,² lantibiotics such as nisin, mersacidin, lacticin, and gallidermin are promising candidates for the development of new antibiotics. Total syntheses of nisin A, lacticin 3147, and lacticin 481 have been accomplished.^{3–5}

*Corresponding Author mvannieu@indiana.edu.

Supporting Information

The Supporting Information is available free of charge on the ACS Publications website at DOI:10.1021/acs.orglett.9b00125.

Experimental procedures, spectroscopic data of the obtained compounds and copies of ¹H and ¹³C NMR spectra (PDF)

The authors declare no competing financial interest.

We have initiated a synthetic effort directed at the lantibiotic mersacidin (Figure 1), which is active against methicillin-resistant *Staphylococcus aureus* (MRSA) and vancomycin-resistant *Enterococcus* (VRE). Mersacidin is believed to inhibit the transglycosylation reaction, a key reaction that results in polymerization of the carbohydrate backbone, during the latter stages of the peptidoglycan biosynthetic pathway.⁶

In order to understand the exact mechanism of action and in order to attempt tuning of biological activity through analog synthesis, we are currently pursuing the chemical synthesis of mersacidin. From a structural standpoint, β -methyllanthionine is embedded in all four rings of mersacidin. In addition, the (*Z*)-aminovinyl sulfide moiety is a derivative of β -methyllanthionine (Figure 1). In order to execute a total synthesis of mersacidin, large quantities of orthogonally-protected β -methyllanthionines were required.

As the characteristic component of lantibiotics, β -MeLan has attracted considerable interest from synthetic chemists. To date, several syntheses of orthogonally-protected β -MeLan have been reported.⁷ In summary, synthesis of β -MeLan has been typically achieved through use of one of the following three approaches (Scheme 1): (i) Lewis acid mediated ring opening of *N*-carbobenzoxyaziridines with cysteine;^{4,8} (ii) ring opening of cyclic sulfamides with cysteine;⁹ and (iii) S_N2 reactions of bromoalanine and β -methylcysteine.¹⁰ However, each of the above methods have their drawbacks, which present difficulties for their application in a large-scale synthesis of β -methyllanthionine.

For example, nucleophilic ring opening of *N*-carbobenzoxyaziridines requires a large excess of BF₃·OEt₂ (4—8 equiv). Furthermore, these reactions are typically sluggish (3—5 days), and the yields are frequently poor (e.g., 12%—46%). The cyclic sulfamate method gives better yields, but it requires cleavage of the intermediate sulfamic acid, involving the use of propanethiol, after the nucleophilic ring-opening reaction.

Additionally, the preparation of the sulfamate precursors requires oxidative conditions that are not compatible with allyl and alloc protecting groups. The bromoalanine route requires multiple synthetic steps to prepare each of the reaction partners, and some of these reactions are plagued by low overall atom efficiencies. As a result, this method is also unsuitable for large-scale synthesis. To facilitate the total synthesis of mersacidin, we felt it was necessary to develop a new method for an efficient and scalable synthesis of orthogonally-protected β -MeLan derivatives.

Direct construction of the carbon—sulfur bond in β -MeLan through nucleophilic ring-opening of an orthogonally-protected *N*-carbobenzoxyaziridine with an orthogonally protected cysteine derivative is highly atom economical. Moreover, the preparation of the required cysteine- and aziridine-derived reaction partners is concise and well-established.¹¹ Various bases, as well as Lewis acids, have been successfully applied for aziridine ring-opening reactions with carbon, nitrogen, sulfur, oxygen, and halogen nucleophiles.^{12,13} To the best of our knowledge, BF₃·OEt₂ is the only Lewis acid that has ever been utilized in the attack of cysteine-derived nucleophile on aziridine. However, as mentioned above, since these reactions typically require large excesses of BF₃·OEt₂, long reaction times, display intolerance toward acid labile protecting groups, and proceed in relatively poor yields, this

reaction is unsuitable for large-scale synthesis of β -MeLan derivatives. These liabilities led us to investigate the development of an alternative method to enable an efficient and scalable synthesis of β -MeLan derivatives via ring opening of suitable protected aziridines by orthogonally-protected cysteine nucleophiles.

The protecting group on the aziridine nitrogen should be electron-withdrawing in order to activate the aziridine toward nucleophilic ring-opening. Given this limitation, our efforts focused on use of the *p*-nitrobenzyloxycarbonyl (*p*-NO₂-Cbz) protecting group. Compared to the Cbz protecting group frequently used in previously reported β -MeLan syntheses, which is difficult to remove by catalytic hydrogenation due to the presence of the sulfur atom, *p*-NO₂-Cbz can be readily removed via catalytic hydrogenation or via reductive cleavage by sodium dithionite.¹⁴ Therefore, cysteine derivative **1a** and aziridine derivative **2a** were chosen as model substrates for our initial investigation seeking suitable Lewis acids or bases that can facilitate the desired ring-opening reaction.

As noted in Table 1, ZnCl₂, Ag(cod)₂PF₆, LiClO₄, In(OTf)₃, and DABCO failed to afford the desired product **3a** (Table 1, entries 1—4 and 6). BiCl₃ and InBr₃ gave **3a** in yields of 20% and 36%, respectively (Table 1, entries 5 and 7). When the mixture of **1a** and **2a** was treated with InCl₃ in DCM at room temperature, product **3a** was obtained in 52% yield (Table 1, entry 8). When the reaction was performed in Et₂O, the yield improved to 62% (Table 1, entry 10). Based on the reaction monitoring by TLC, the improved yield was attributed to suppressed Boc protecting group cleavage when the reaction was carried out in Et₂O relative to DCM. A reduction of the amount of InCl₃ (Table 1, entries 9 and 11) resulted in increased reaction times and increased product decomposition. This trend was further exacerbated when catalytic amounts of InCl₃ were employed. Further experimentation revealed that 1 molar equiv of InCl₃ in Et₂O at room temperature provided the optimal conditions for the desired aziridine ring-opening reaction.

With the optimal conditions identified in our model reaction system, the substrate scope was subsequently investigated. As shown in Scheme 2, a variety of cysteine derivatives performed well in the InCl₃-mediated aziridine ring-opening reactions to provide β -MeLan derivatives (e.g., **3a—c,e,f**) in good yields. To our delight, the reaction also worked well when the C-terminal cysteine carboxyl group was not protected; **3g** and **3h** were obtained in yield of 88% and 50%, respectively. These products can be directly utilized for further peptide assembly or for direct preparation of unusual *S*-[(*Z*)-2-aminovinyl]-(3*S*)-3-methyl-D-cysteine (AviMeCys)—an important unit of several lantibiotics (including mersacidin) with highly potent biological activities—via diphenylphosphoryl azide (DPPA)-mediated decarboxylation¹⁵ or Ni-promoted decarbonylation of amino acid thioesters.¹⁶ In general, our data appear to support the notion that better yields are obtained in reactions that do not utilize reaction partners with acid-labile protecting groups (e.g., Boc, *tert*-butyl).

After the exploration of the substrate scope, we tested our optimized substrates and reaction conditions for a large-scale synthesis of β -MeLan (Scheme 3). To our delight, the yields remained consistent with those observed in our model systems when the reactions were carried out on a small scale. For example, reactions 1 and 2 (Scheme 3) proceeded smoothly to deliver over 30g of β -MeLan **3g** and **3b** in yields of 86% and 62%, respectively.

To further demonstrate the utility of this chemistry, β -MeLan derivative **3e** was readily converted into the A-ring of mersacidin. Cleavage of the *p*-NO₂-Cbz group and the *p*-nitrobenzyl group in β -MeLan **3e**, via reductive cleavage with sodium dithionite, followed by cyclization of the resulting 3 amino acid through activation with diphenylphosphoryl azide afforded the orthogonally protected A-ring of mersacidin in 25% yield over the two-step sequence.

In summary, we have developed a rapid and efficient synthesis of orthogonally-protected β -methyllanthionines via indium(III)-mediated nucleophilic ring opening of aziridines under mild conditions. The reaction conditions tolerated various protecting groups schemes, and large quantities of β -methyllanthionines can be produced in a single batch. The development of this efficient method to quickly access β -methyllanthionines, in quantity, will substantially assist efforts directed at the total synthesis of mersacidin and other lantibiotics. Our own efforts in this area will be reported in due course.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

ACKNOWLEDGMENTS

We thank Indiana University and the National Institutes of Health (GM 111537) for financial support.

REFERENCES

- (1). Solomon SL; Oliver KB Antibiotic Resistance Threats in the United States: Stepping Back from the Brink. *American Family Physician* 2014, 89, 938–941. [PubMed: 25162160]
- (2). Chatterjee C; Paul M; Xie L; van der Donk WA Biosynthesis and Mode of Action of Lantibiotics. *Chem. Rev* 2005, 105, 633–684. [PubMed: 15700960]
- (3). Fukase K; Kitazawa M; Sano A; Shimbo K; Fujita H; Horimoto S; Wakamiya T; Shiba T Total synthesis of peptide antibiotic nisin. *Tetrahedron Lett.* 1988, 29, 795–798.
- (4). Liu W; Chan AS; Liu H; Cochrane SA; Vederas JC Solid supported chemical syntheses of both components of the lantibiotic lactacin 3147. *J. Am. Chem. Soc* 2011, 133, 14216–9. [PubMed: 21848315]
- (5). Knerr PJ; van der Donk WA Chemical synthesis of the lantibiotic lactacin 481 reveals the importance of lanthionine stereochemistry. *J. Am. Chem. Soc* 2013, 135, 7094–7. [PubMed: 23621626]
- (6). Brötz H; Bierbaum G; Reynolds PE; Sahl H-G The Lantibiotic Mersacidin Inhibits Peptidoglycan Biosynthesis at the Level of Transglycosylation. *Eur. J. Biochem* 1997, 246, 193–199. [PubMed: 9210483]
- (7) (a). Denoel T; Lemaire C; Luxen A Progress in Lanthionine and Protected Lanthionine Synthesis. *Chem. - Eur. J* 2018, 24, 15421–15441. [PubMed: 29714402] (b) Tabor AB The challenge of the lantibiotics: synthetic approaches to thioether-bridged peptides. *Org. Biomol. Chem* 2011, 9, 7606. [PubMed: 21960309]
- (8). Nakajima K; Oda H; Okawa K. Studies on 2-Aziridinecarboxylic Acid. IX. Convenient Synthesis of Optically Active S-Alkylcysteine, threo-S-Alkyl- β -methylcysteine, and Lanthionine Derivatives via the Ring-opening Reaction of Aziridine by Several Thiols. *Bull. Chem. Soc. Jpn* 1983, 56, 520–522.
- (9). Cobb SL; Vederas JC A concise stereoselective synthesis of orthogonally protected lanthionine and β -methyllanthionine. *Org. Biomol. Chem* 2007, 5, 1031–8. [PubMed: 17377656]

- (10). Narayan RS; VanNieuwenhze MS. Versatile and Stereoselective Syntheses of Orthogonally Protected β -Methylcysteine and β -Methylanthionine. *Org. Lett* 2005, 7, 2655–2658. [PubMed: 15957914]
- (11). See the Supporting Information.
- (12). Hu XE Nucleophilic ring opening of aziridines. *Tetrahedron* 2004, 60, 2701–2743.
- (13). Stamm H Nucleophilic ring opening of aziridines. *J. Prakt. Chem* 1999, 341, 319–331.
- (14). Maity P; Reddy VVR; Mohan J; Korapati S; Narayana H; Cherupally N; Chandrasekaran S; Ramachandran R; Sfougataki C; Eastgate MD; Simmons EM; Vaidyanathan R Development of a Scalable Synthesis of BMS-978587 Featuring a Stereospecific Suzuki Coupling of a Cyclopropane Carboxylic Acid. *Org. Process Res. Dev* 2018, 22, 888–897.
- (15). Carrillo AK; VanNieuwenhze MS Synthesis of the AviMeCys-Containing D-Ring of Mersacidin. *Org. Lett* 2012, 14, 1034–1037. [PubMed: 22296295]
- (16). García-Reynaga P; Carrillo AK; VanNieuwenhze MS Decarbonylative Approach to the Synthesis of Enamides from Amino Acids: Stereoselective Synthesis of the (Z)-Aminovinyl-D-Cysteine Unit of Mersacidin. *Org. Lett* 2012, 14, 1030–1033. [PubMed: 22296268]

Figure 1.
Structure of β -methylanthionine and mersacidin.

i) Ring opening of aziridines

ii) Ring opening of sulfamidates

iii) Synthesis from bromoalanine

Scheme 1. Previous Approaches to Orthogonally-Protected β -Methylanthionine

Scheme 2. Substrate Scope of the InCl_3 -Mediated Ring-Opening Reaction of Cysteines and Aziridines^a

^aAll reactions were carried out with 1 (2.5 mmol), 2 (2.5 mmol), and InCl_3 (1.0 equiv) in Et_2O (25 mL) at 25 °C.

Scheme 3. Thirty-Gram Scale Synthesis of β -MeLan and Synthesis of the A Ring of Mersacidin

Table 1.Optimization of the Reaction Conditions for Nucleophilic Ring-Opening of **2a** with **1a**^a

entry	catalyst	solvent	yield (%)
1	DABCO	DCM	0
2	ZnCl ₂	DCM	0
3	Ag(cod) ₂ PF ₆	DCM	0
4	LiClO ₄	DCM	0
5	BiCl ₃	DCM	20
6	In(OTf) ₃	DCM	0
7	InBr ₃	DCM	36
8	InCl ₃	DCM	52
9	InCl ₃	DCM	46 ^b
10	InCl ₃	Et ₂ O	62
11	InCl ₃	Et ₂ O	56 ^b

^a **1a** (1 equiv), **2a** (1 equiv), catalyst (1 equiv).^b InCl₃ (30 mol %), 16 h